Investing.com -- Kura Oncology (NASDAQ:KURA) shares rose 9% Friday following the release of preliminary trial data showing its drug combination demonstrated activity in patients with clear cell renal ...
Data from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treat ...
Twenty-seven years ago today, a Broadway legend who also wrote a long list of hit songs died of cancer in Florida.
Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...
The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...
5d
XORTX Therapeutics Inc.: XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset
VB4-P5 - novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results